/PRNewswire/ Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug.
- Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US Phase I/II trial with ADC designed to treat solid tumors - MRG004A selected for clinical development based